EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications

Yunjie Ge iD, Yangyang He iD, Shili Yu iD, Hongwen Gao iD, Ping-Li Sun iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e73 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Yunjie Ge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Second Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Homologous Recombination. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate the clinicopathological and prognostic significance of homologous recombination deficiency (HRD) in high-grade serous ovarian carcinoma (HGSC) and evaluate the impact of neoadjuvant chemotherapy (NACT) on HRD detection. METHODS: HRD status was assessed in 126 surgically resected HGSC samples (30 post-NACT, 96 primary surgery) using the AmoyDx® HRD Complete Panel. HRD positivity was defined as a pathogenic/likely pathogenic BRCA1/2 mutation and/or genomic scar score (GSS) ≥45. Correlations with clinicopathological variables, histological subtypes (classic vs. solid, endometrial-like, and transitional [SET] patterns), and survival were analyzed. RESULTS: HRD positivity was detected in 76 (60.3%) cases, with BRCA1/2 mutations in 26.2%. HRD-positive tumors showed larger size (p=0.034) and more SET patterns (p=0.001). Notably, among BRCA1/2 wild-type patients, the NACT group showed significantly lower HRD positivity (22.2% vs. 56.1%; p=0.003) and decreased median GSS (19.5 vs. 55.2; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousHomologous RecombinationHumansFemaleNeoadjuvant TherapyPrognosisMiddle AgedAgedMutationAdultChemotherapy, AdjuvantBRCA1 ProteinBRCA2 ProteinNeoplasm Grading

Stichwörter der Autor:innen

Homologous RecombinationNeoadjuvant TherapyOvarian NeoplasmsPathology, ClinicalPrognosisSerous Cystadenocarcinoma

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, The Second Hospital of Jilin University, Changchun, China.
  • Department of Pathology, The Second Hospital of Jilin University, Changchun, China. pinglisun@jlu.edu.cn.

ORCID-Profile: Yunjie Ge, Yangyang He, Shili Yu, Hongwen Gao, Ping-Li Sun

Zitieren

APA

Ge, Y., He, Y., Yu, S., Gao, H., & Sun, P. L. (2026). Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e73

Vancouver

Ge Y, He Y, Yu S, Gao H, Sun PL. Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e73

BibTeX
@article{Ge2026,
  author = {Ge, Yunjie and He, Yangyang and Yu, Shili and Gao, Hongwen and Sun, Ping-Li},
  title = {Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e73}
}
Kostenlos starten →